An Integrated Safety and Efficacy Analysis of Phase 3 ECOSPOR III and ECOSPOR IV Studies of Fecal Microbiota Spores, live-brpk (Vost TM; VOS; Formerly SER-109) in Recurrent Clostridioides difficile Infection

Authors

Anne J. Gonzales-Luna
Matthew D. Sims, Beaumont Health
David A. Lombardi
Lisa von Moltke
Sissi V. Pham

Document Type

Conference Proceeding - Restricted Access

Publication Date

12-2023

Publication Title

Journal of the American College of Clinical Pharmacy

Volume

6

Issue

12

First Page

1481

Comments

2023 ACCP American College of Clinical Pharmacy Annual Meeting, November 11-14, 2023, Dallas, TX

Recommended Citation

Gonzales-Luna AJ, Sims MD, Lombardi DA, von Moltke L, Pham SV. An integrated safety and efficacy analysis of phase 3 ECOSPOR III and ECOSPOR IV studies of fecal microbiota spores, live-brpk (Vowst TM; VOS: formerly SER-109) in recurrent Clostridioides difficile infection. J Am Coll Clin Pharm. 2023 Dec;6(12):1481. doi:10.1002/jac5.1903.

DOI

10.1002/jac5.1903